Boyle Kevin S. Sr. 4
4 · ZIOPHARM ONCOLOGY INC · Filed Nov 17, 2021
Insider Transaction Report
Form 4
Boyle Kevin S. Sr.
DirectorChief Executive Officer
Transactions
- Purchase
Common Stock
2021-11-16$1.40/sh+884$1,238→ 875,884 total - Purchase
Common Stock
2021-11-17$1.40/sh+9,116$12,762→ 885,000 total